Chemomab Therapeutics Ltd. (NASDAQ:CMMB) Sees Large Growth in Short Interest

Chemomab Therapeutics Ltd. (NASDAQ:CMMB) was the target of a significant growth in short interest in the month of December. As of December 15th, there was short interest totalling 111,600 shares, a growth of 8.2% from the November 30th total of 103,100 shares. Approximately 0.7% of the company’s shares are sold short. Based on an average trading volume of 118,500 shares, the days-to-cover ratio is presently 0.9 days.

Analyst Ratings Changes

Separately, Oppenheimer restated an “outperform” rating and issued a $11.00 target price (down previously from $13.00) on shares of Chemomab Therapeutics in a report on Friday, November 15th.

Chemomab Therapeutics Trading Down 10.4 %

NASDAQ:CMMB traded down $0.21 on Wednesday, hitting $1.81. 125,418 shares of the company’s stock traded hands, compared to its average volume of 176,470. The firm has a 50-day moving average price of $1.65 and a 200-day moving average price of $1.46. The company has a market cap of $25.99 million, a PE ratio of -1.81 and a beta of 0.66. Chemomab Therapeutics has a 1 year low of $0.46 and a 1 year high of $2.55.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Chemomab Therapeutics stock. Sphera Funds Management LTD. bought a new position in Chemomab Therapeutics Ltd. (NASDAQ:CMMB) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 1,214,575 shares of the company’s stock, valued at approximately $1,907,000. Sphera Funds Management LTD. owned about 8.46% of Chemomab Therapeutics at the end of the most recent reporting period. 46.05% of the stock is owned by hedge funds and other institutional investors.

About Chemomab Therapeutics

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).